0001209191-24-000764.txt : 20240104 0001209191-24-000764.hdr.sgml : 20240104 20240104161521 ACCESSION NUMBER: 0001209191-24-000764 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240102 FILED AS OF DATE: 20240104 DATE AS OF CHANGE: 20240104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Janku Filip CENTRAL INDEX KEY: 0001862930 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40522 FILM NUMBER: 24512068 MAIL ADDRESS: STREET 1: MONTE ROSA THERAPEUTICS, INC. STREET 2: 40 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02134 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Monte Rosa Therapeutics, Inc. CENTRAL INDEX KEY: 0001826457 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 321 HARRISON AVENUE STREET 2: SUITE 900 CITY: BOSTON STATE: MA ZIP: 02118 BUSINESS PHONE: 617-949-2643 MAIL ADDRESS: STREET 1: 321 HARRISON AVENUE STREET 2: SUITE 900 CITY: BOSTON STATE: MA ZIP: 02118 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2024-01-02 0 0001826457 Monte Rosa Therapeutics, Inc. GLUE 0001862930 Janku Filip MONTE ROSA THERAPEUTICS, INC. 321 HARRISON AVENUE, SUITE 900 BOSTON MA 02118 0 1 0 0 Chief Medical Officer 0 Common Stock 5252 D Stock Option (Right to Buy) 5.71 2024-01-02 4 A 0 121000 0.00 A 2034-01-01 Common Stock 121000 121000 D Includes an aggregate of 5,252 shares previously acquired under the Issuer's 2021 Employee Stock Purchase Program. 25% of this option shall vest and become exercisable on January 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. /s/ Markus Warmuth, Attorney-in-Fact 2024-01-04